Latest 6 stories · newest Nov 5, 2026
Viatris reported Q3 revenues of $3.75B and raised its 2026 guidance. The company also received regulatory approvals and announced the planned acquisition of Pacira BioSciences, coupled with $717M in capital returned to shareholders.
Pacira Biosciences Inc and Viatris Inc entered into an agreement and plan of merger. The transaction, dated October 8, 2026, involves the merger of Pacira into Viatris.
Viatris reported Q2 2026 Total Revenues of $3.8B and Adjusted EBITDA of $1.2B. The company raised full-year 2026 guidance and returned $550M to shareholders.
Viatris Inc. entered into an amended and restated international term loan credit agreement dated July 1, 2026. This facility replaces the company's prior arrangement with Mizuho Bank, MUFG, and SMBC.
Viatris Inc. completed an underwriting agreement to issue €650 million in senior notes due 2033 with a 4.250% coupon, guaranteed by Mylan Inc. and subsidiaries. The debt offering provides capital for the pharmaceutical company and is underwritten by major investment banks including BNP Paribas, Citi…
The same VTRS feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/VTRS/newsSTART FREE